Smith & Nephew buys OsteoBiologics for $72.3m
This article was originally published in Clinica
In a bid to bulk up its arthroscopy portfolio, Smith & Nephew's endoscopy division has acquired for $72.3m OsteoBiologics, the US company behind the Tru brand of bioabsorbable tissue-engineered scaffolds used in the repair and regeneration of musculoskeletal tissue.
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Guidelines outline permitted practices and patient safeguards for both physicians and technology platforms.
Executives at Pfizer and Moderna expressed confidence in their US government partners for initial COVID-19 vaccine distribution and expect pediatric studies to begin before the end of the year. Regeneron will “do the right thing” in pricing its antibody cocktail.